Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great!
Answer 1. Overcoming local and systemic tumor immune suppression is enough to completely eliminate cancer from the body over time (IMHO) if you are also using the full complement of tumor biomarkers. ICT-107 and other gene jockey methods not only do not use partial maturation to overcome local and systemic tumor and tumor microenvironment immune suppression, but they also hamstring themselves by only using a few random antigens when there are hundreds of tumor antigens, and even different antigens in different tumors throughout the body.
If DCVax-Direct used perfect partial maturation but only a few antigens, it would not be enough. If DCVax-Direct used all the antigens available in all the tumors, but it did not use perfect partial dendritic cell maturation, it would not be enough. Thankfully, DCVax-Direct did not skimp on its technology.
Answer 2. This technology was developed and perfected over many years. The DCVax-Direct preclinical and clinical trial pathology, observations and other results thus far present no reason to suggest the mechanism of action is significantly different than the MOA Bosch and Boynton perfected their patents upon, and that Liau and Prins helped develop through their work at UCLA.
Thus the title for the 2014 SITC abstract should, for all intensive purposes be claiming a result that is based upon the MOA that was/is being carefully perfected to the exact hour and dose -- even in the upcoming phase 2 multi-injection trial starting this fall. That perfection is being conducted based upon well documented advantages previously described and detailed by Doctor's Bosch and Boynton in their patents, by NWBIO in their literature, by other similar peer reviewed preclinical and clinical trials, including the recent phase 2 DCVax-Direct trial abstract published by UCLA -- and indirectly by many other dendritic cell preclinical and clinical trial efforts. (You may have noticed, I've been going to the trouble of reprinting and explaining more NWBIO literature today.) IMHO.
A diagram of some key agents and weapons of the immune system is set forth: (Also see explanation following diagram)
( Note:Keep thinking about this sentence as you digest this information: "Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment.")
Extensive scientific evidence has shown that there is substantial variation in tumor profiles and characteristics among patients with the “same” cancer. The degree of variation is particularly enormous in some of the most aggressive cancers, such as GBM brain cancer and pancreatic cancer. DCVax is designed to target the full set of biomarkers on a patient’s cancer. Such a treatment approach makes it more difficult for tumors to develop escape variants. Source: NWBIO Website
Pyrr penned a terrific article with great attention to current considerations.
In contradiction to what AF once said, there are many articles written about Dendritic therapy.
I'm simply a poster with shares in NWBO. I have no other connection with NWBO whatsoever -- except perhaps my wish that cancer is but a memory. I read a lot, as do Pyrr and other posters.
I really am a very long investor, so I do not attempt to time the market. That said, here is part of a comment I just left on Pyrr's recent article:
Les Goldman's 2 cents on biotech Short manipulation.
(I say this indirectly, because the quote below suggests Goldman believes small biotech's are vulnerable to short manipulation, which is what the article was about, prior to crossing a particular threshold in market cap size.)
(May or may not be not be an accurate quote, because the author had a pro-AF agenda.)
I object to the misleading and false statements intentionally and crudely shouted by AF from his bully pulpit. I know he knows the rules, and that is what makes his frequent lies and damn lies all the more infuriating.
I think 1-2 years for complete availability is spot on. 12 months - 18 months until global availability for DCVax-L, and 18 months to 24 months until global availability for DCVax-Direct. IMHO. I am sorry for your losses, and I believe those who went before us will somehow see this journey through with us.
One more time....
I'm pretty certain Roy has a different take on this.
Perhaps one must take it to the streets, in order to take it to The Street....
Hi Retiredinlovinglight,
Here is something I wrote recently, which kind of jives with your numbers.
I won't get too caught up in analogies here, the proof will come in the pudding:) From here forward, I'm focused on results. Financially, NWBO can see themselves through phase I Direct results and phase III L results with minor/moderate financing. The trial results will either catapult us into the stratosphere, or they will not. I believe they will, and I think NWBO management is keeping their powder dry for November and December 2014. That will likely bring us up to a much higher base, then we will likely have a lull until the end of March 2015, a higher base, then another lull until ASCO in May/June and an astronomically high base. The advancements after that will be during such time that NWBO is a household name. IMHO.
Blessings to Ethan, his family and his community.
I'm afraid we are currently rocket scientists in this household, and my offspring and I fully intend to break the 1200 foot limit set by Quest Aerospace's rocket starter set. However, you may be gratified to know that our mutual brain power confirms your sensible conclusion.
A symbolic gesture?
ASCO (Amercan Society of Clinical Oncology) shares the same side of the street with NWBO:)
I'm very sorry to hear about your dog. I hope that the animal vaccine will be rekindled once the human versions are marketed. Direct will likely be a much better option for animals, as many owners simply can't afford surgery plus treatment. Beyond pets, the global agricultural industry may help finance this technology as well.
Thanks antihama
Granted, an Artist's rendering.
Still, timeless discoveries provide elegance.
Nanotube and Bucky-Ball
Serene Structure for Engineers
Dendritic Cell and Double Helix
Exquisite Entanglement for Biologists
Carbon Atom and Water Molecule
Continuous Composition for Chemists
Relativity and Quantum Mechanics
Certain Chance for Physicists
Granted, an Artist's rendering.
The current short interest numbers only bring it current to October 15, 2014. Any short covering since that time will not be reported until November 11, 2014, and that will only reflect short interest through Halloween.
How DCVax-Direct Overcomes Local and Systemic Tumor Immune Suppression.
(Reprinted for a better sticky title.)
I'm going to try and explain this at a more digestible level -- per request.
1. DCVax-Direct (Dendritic cells) is/are injected into a cancer tumor.
2. DCVax immediately secretes (releases) massive amounts of cytokines (natural chemicals) that kill tumor cells, create inflammation and signal the innate (early) immune system (e.g. Natural Killer Cells) to respond. This is just the beginning.
3. The DCVax dendritic cells start nibbling on the dead tumor debris. Because these are special dendritic cells, the tumor cannot use its normal toolkit of different cytokines (natural chemicals) to stop the dendritic cell from ingesting this dead tumor debris. Just call them the teflon DCs.
4. After dining on the tumor debris, the dendritic cell processes the dead tissue into tinier fragments scientists call antigens, and the DC actually displays these dead tumor parts (antigens) on the dendritic cell surface. Again, normally the tumor environment would stop or interfere with dendritic cells trying to process and display dead tumor debris (antigens), but not our DCVax dendritic cells. They are like super-mailmen undeterred by local lousy conditions, and intent on making their appointed rounds.
5. Now the dendritic cells escape the tumor micro-environment laden heavy with a dense coating of tumor antigens on their surfaces. Again, here the DCVax-Direct dendritic cell carries far more antigens packed upon its surface than any common dendritic cell might.
6. Next, the dendritic cell literally crawls through the extracellular matrix toward a nearby lymph node. Again, the DCVax dendritic cell is not slowed by the prior tumor environment attempts to weaken it before its journey.
7. Upon arrival at the lymph node, most dendritic cells would have been previously weakened by chemicals released by the tumor microenvironment both inside and outside the tumor; instead, the DCVax dendritic cell is still completely able to (hyper) activate t-cells and b-cells to multiply and attack the intended target.
8. These t-cells and b-cells are so well instructed/activated that they immediately proliferate into the millions and seek out tumor cells throughout the body.
9. The primary tumor, now weakened by the dendritic cytokines and innate immune system, is attacked by the SUPER t-cells and b-cells. Next, other tumors throughout the body are likewise attacked.
10. These members of the adaptive immune system are not fooled or blocked by the tumor, as non-DCvax activated t and b-cells might otherwise be. They finish off the tumors and store their description in long lived memory cells that will mount a faster immune system attack should the same cancer try to return.
An easy summer read, a light bedtime story.....not!
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841205/
OK. I'm going to try and explain it at a more digestible level.
1. DCVax-Direct (Dendritic cells) is/are injected into a cancer tumor.
2. DCVax immediately secretes (releases) massive amounts of cytokines (natural chemicals) that kill tumor cells, create inflammation and signal the innate (early) immune system to respond. This is just the beginning.
3. The DCVax dendritic cells start nibbling on the dead tumor debris. Because these are special dendritic cells, the tumor cannot use its normal toolkit of different cytokines (natural chemicals) to stop the dendritic cell from ingesting this dead tumor debris. Just call them the teflon DCs.
4. After dining on the tumor debris, the dendritic cell processes the dead tissue into tinier fragments scientists call antigens, and the DC actually display these dead tumor parts (antigens) on the dendritic cell surface. Again, normally the tumor environment would stop or interfere with dendritic cells trying to process and display dead tumor debris (antigens), but not our DCVax dendritic cells. They are like super-mailmen undeterred by local lousy conditions, and intent on making their appointed rounds.
5. Now the dendritic cells escape the tumor micro environment laden heavy with a dense coating of tumor antigens on their surfaces. Again, here the DCVax dendritic cell carries far more antigens packed upon its surface than any common dendritic cell might.
6. Next, the dendritic cell literally crawls through the extracellular matrix toward a nearby lymph node. Again, the DCVax dendritic cell is not slowed by the prior tumor environment attempts to weaken it before its journey.
7. Upon arrival at the lymph node, most dendritic cells would have been previously weakened by chemicals released by the tumor microenvironment both inside and outside the tumor; instead, the DCVax dendritic cell is still completely able to fully/hyper activate t-cells and b-cells to multiply and attack the intended target.
8. These t-cells and b-cells are so well instructed that they immediately proliferate into the millions and seek out tumor cells throughout the body.
9. The primary tumor, now weakened by the dendritic cytokines and innate immune system, is attacked by the SUPER t-cells and b-cells. Next, other tumors throughout the body are likewise attacked.
10. These members of the adaptive immune system are not fooled or blocked by the tumor, as non-DCvax activated t and b-cells might otherwise be. They finish off the tumors and store their memory in long lived memory cells that will attack should they try to return.
Thanks Evaluate!
Good points Pyrr. I thought I'd throw this in from the 2012 DCVax patent for those who are interested.
In it, please note that partially mature dendritic cells can uptake tumor debris, process antigens, present antigens at higher density levels and create stronger t-cell activation. The SITC statement confirms DCVax-Direct is able to do this without interference by the tumor microenvironment both within the tumor and systemically (e.g.. at the lymph during presentation and activation)!
Afford, to me, the title suggests DCVax-Direct works exactly the way it is supposed to. Bosch, Boynton and Liau have been tinkering and collaborating over the past 10-15 years to perfect DCVax-Direct. This includes but is not limited to perfecting resistance against tumor suppression, increasing initial cytokine induced tumor death, increasing uptake and expression through proper maturity, eliminating dendritic cells prior to injection that would have the opposite effect, increasing t-cell proliferation, tumor cell targeting and the list goes on.
When Direct works the way it is supposed to, it stops, kills and eventually (over weeks and months) eliminates tumors from the patient. Finally, it should prevent cancer from returning (durability/immune memory). We are still awaiting future presentations to learn what degree of success these trials are demonstrating in humans.
Yes, I am in agreement with Pyrr's statement, but it should read "tumor necrosis." (not just necrosis). However, you must also hit the right target. That is why the section I highlighted in red below is included in my last message.
The title suggests that anti-PD1 therapies are not necessary for DCVax-Direct to overcome local and systemic immune suppression imposed by the tumor and its microenvironment.
Maybe this is a poor way for me to describe what the SITC NWBO title potentially means, but this is extremely significant because it intimates that adjuvants are not necessary to make DCVax-Direct effective.
If tumors cannot mount suppression against dendritic cells, one can infer that they are also not mounting effective tumor response against the t and b cells activated by the dendritic cells. This is why the last part of the SITC sentence is so important.
By November 4, 2014, nearly 5 months will have gone by since the last significant DCVax-Direct update. That's a lot of pent-up data.
Best wishes to patients.
10 days until the embargo is lifted.
No it doesn't. It sounds like a small company doing far better than you could at developing an international infrastructure, new processing platform, intergovernmental relations for regulatory support, and oh yeah....a possible cure for cancer -- all on a relative shoe string budget.